BWM
SRNE

Baystate Wealth Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Baystate Wealth Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-200
Closed – – 764
2020
Q1 		$0 Buy
+200
New +$576 ﹤0.01% 701

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Baystate Wealth Management's SRNE Position: Q2 2020 in Review

Baystate Wealth Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q2 2020, closing a stake of 200 shares.

Baystate Wealth Management first reported a position in SRNE in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 186 funds tracked by Wall St. Rank hold SRNE as of Q2 2020.

  • Baystate Wealth Management reported no remaining Sorrento Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Baystate Wealth Management sold 200 Sorrento Therapeutics, Inc. shares in Q2 2020.
  • Baystate Wealth Management first reported a position in Sorrento Therapeutics, Inc. in Q1 2020 and held it in 1 quarter.
  • Baystate Wealth Management's Sorrento Therapeutics, Inc. position peaked at $0 in Q1 2020.
  • 186 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q2 2020.

Based on Baystate Wealth Management's 13F filing for Q2 2020, filed 28 Jul 2020.